Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Bracarda

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
European Urology|April 21, 2007
Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experienceSergio Bracarda
European Urology|February 20, 2007
Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II studySergio Bracarda
Expert Opinion on Pharmacotherapy|January 24, 2012
3rd Pavia international symposium on advanced kidney cancerCamillo Porta, Sergio Bracarda
European Urology|September 10, 2008
Sequential therapies in metastatic renal cell carcinoma: option or strategy?Sergio Bracarda, Valeria De Simone
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|June 23, 2004
[The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer]Sergio Bracarda, Claudia Caserta, Maurizio Tonato
The Journal of Urology|June 23, 2017
Editorial CommentSergio Bracarda, Simona Duranti, Giandomenico Roviello
European Urology|July 22, 2018
"To Cut or Not to Cut", a Biomolecular Approach to Metastasectomy in Metastatic Clear Cell Renal Cell CarcinomaSergio Bracarda, Annalisa Guida, Claudia Caserta
European Urology|December 4, 2014
Steroids in prostate cancer: the jury is still out... and even more confusedCamillo Porta, Sergio Bracarda, Romano Danesi
Advances in Respiratory Medicine|June 22, 2022
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>PAnnalisa Guida, Valentina Tassi, Francesco Facchinetti, et al.
Critical Reviews in Oncology/Hematology|November 15, 2018
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS ReviewSergio Bracarda, Camillo Porta, Roberto Sabbatini, et al.
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
European Urology|April 21, 2007
Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experienceSergio Bracarda
European Urology|February 20, 2007
Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II studySergio Bracarda
Expert Opinion on Pharmacotherapy|January 24, 2012
3rd Pavia international symposium on advanced kidney cancerCamillo Porta, Sergio Bracarda
European Urology|September 10, 2008
Sequential therapies in metastatic renal cell carcinoma: option or strategy?Sergio Bracarda, Valeria De Simone
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|June 23, 2004
[The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer]Sergio Bracarda, Claudia Caserta, Maurizio Tonato
The Journal of Urology|June 23, 2017
Editorial CommentSergio Bracarda, Simona Duranti, Giandomenico Roviello
European Urology|July 22, 2018
"To Cut or Not to Cut", a Biomolecular Approach to Metastasectomy in Metastatic Clear Cell Renal Cell CarcinomaSergio Bracarda, Annalisa Guida, Claudia Caserta
European Urology|December 4, 2014
Steroids in prostate cancer: the jury is still out... and even more confusedCamillo Porta, Sergio Bracarda, Romano Danesi
Advances in Respiratory Medicine|June 22, 2022
Ad hoc afatinib in an eldery lung cancer patient with EGFR exon 19 deletion L747-A750>PAnnalisa Guida, Valentina Tassi, Francesco Facchinetti, et al.
Critical Reviews in Oncology/Hematology|November 15, 2018
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS ReviewSergio Bracarda, Camillo Porta, Roberto Sabbatini, et al.
Pageof 18